Browsing Tag
Lupin Limited
41 posts
Lupin secures US FDA approval for generic Fesoterodine Fumarate Extended-Release Tablets in overactive bladder treatment market
Lupin secures US FDA approval for generic Fesoterodine Fumarate ER tablets, entering a USD 177M overactive bladder market in the United States.
Lupin launches authorized generic of PENNSAID in US to tap $509m osteoarthritis knee pain market
Lupin launches the authorized generic of PENNSAID in the U.S., targeting the $509M osteoarthritis knee pain market with a proven, cost-effective NSAID solution.
Is this Lupin’s next U.S. respiratory blockbuster? Generic Perforomist hits the shelves
Lupin launches generic Perforomist in the U.S. for asthma and COPD, eyeing a $268M market. Find out how this move boosts its global respiratory portfolio.
Lupin Limited secures US FDA tentative approval for generic version of rosacea drug Oracea
Lupin Limited gains US FDA tentative approval for generic Oracea, targeting the $215M rosacea drug market in the US.
Lupin secures US FDA tentative approval for generic version of Slynd contraceptive tablets
Lupin wins US FDA tentative approval for generic drospirenone contraceptive, targeting a $141M US market. See how this move fits its women’s health strategy.
Lupin secures FDA approval to launch generic vigabatrin oral solution in the US market
Lupin secures US FDA approval for generic vigabatrin oral solution, a $275M epilepsy drug, boosting its US generics and neurology portfolio.
Dialysis care boost: Lupin Limited wins USFDA green light for Renvela-equivalent packets, targeting a $51.7m market
Find out how Lupin Limited’s USFDA approval for Sevelamer Carbonate oral suspension could reshape U.S. dialysis procurement and patient access today.
Lupin enters Brazilian oncology biosimilars market with Biomm deal for Pegfilgrastim
Lupin partners with Biomm SA to bring biosimilar Pegfilgrastim to Brazil, expanding oncology supportive care access and entering Latin America’s biologics market.
Lupin launches generic Fenofibrate Capsules in US to target cholesterol management market
Lupin launches generic Fenofibrate Capsules in the U.S., expanding its cardiovascular portfolio and targeting the cholesterol management market.
Lupin secures FDA approval for generic Truvada, expanding HIV treatment and prevention portfolio in the US
Lupin secures US FDA approval for its generic version of Truvada, targeting HIV treatment and prevention. See what this means for the $2.1B US market.